Navigation Links
EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
Date:10/31/2013

the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase 2 trial for ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, and expecting to initiate a Phase 2 study in ovarian clear cell carcinoma.  ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma, and is expecting to initiate a Phase 2 study in ovarian clear cell carcinoma.  The Company is headquartered in Rockville, Maryland and has a wholly-owned subsidiary in Beijing, China.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with re
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports Second Quarter 2013 Financial Results
2. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
3. EntreMed Reports First Quarter 2013 Financial Results
4. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
5. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
6. EntreMed Announces Changes to Board of Directors and CEO Appointment
7. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
10. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
11. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015 Axxess , an industry leader ... software vendor accredited by the American Nursing Credentialing Center ... health agencies select the right revenue cycle management (RCM) ... their business. Research by American Health Information ... expect a decrease in productivity of 54.4 - 69 ...
(Date:6/29/2015)... 29, 2015 The Parenteral Drug Association is ... Board of Professional Engineers and Land Surveyors ... to professional engineers for continuing professional competency (CPC) credits. ... value and quality of PDA,s professional education offerings," said ... and hands-on professional training at the Training and Research ...
(Date:6/29/2015)... EASTON, Mass. , June 29, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale ... preparation solutions to the worldwide life sciences industry, ... the Institute of Molecular Systems Biology, ETH Zurich, ... proteomic profiling and classification of prostate cancer tissue ...
Breaking Medicine Technology:Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 2Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 3Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 4
... Feb. 21, 2012 A collaboration between NineSigma and ... advance HIV vaccine research by identifying new approaches to ... provider of innovation services , NineSigma has connected ... and helped it identify two scientists who will receive ...
... #8116 -- Precyse, a leader in health information ... HIMSS 2012 Annual Conference and Exposition that the ... improvements in revenue cycle workflow, coding accuracy, and ... adopting Precyse,s integrated health information management (HIM) and ...
Cached Medicine Technology:IAVI and NineSigma Collaborate to Identify New Approaches to Developing AIDS Vaccines 2IAVI and NineSigma Collaborate to Identify New Approaches to Developing AIDS Vaccines 3IAVI and NineSigma Collaborate to Identify New Approaches to Developing AIDS Vaccines 4Growing List of Providers Accelerate Revenue Cycles, Improve Clinical Documentation Through True Computer-Assisted Coding with Natural Language Comprehension™ 2Growing List of Providers Accelerate Revenue Cycles, Improve Clinical Documentation Through True Computer-Assisted Coding with Natural Language Comprehension™ 3Growing List of Providers Accelerate Revenue Cycles, Improve Clinical Documentation Through True Computer-Assisted Coding with Natural Language Comprehension™ 4
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... “It ... and founder of SunGrubbies.com. “We are particularly interested in getting the word out ... take years to surface. We are extremely pleased with our new video ...
(Date:6/29/2015)... ... June 30, 2015 , ... Aespala Medspa and Plastic Surgery is proud ... David Dreyfuss. , Dr. Dreyfuss received his medical degree from Emory University in ... by a Plastic Surgery Fellowship at the University of Chicago. He has taught and ...
(Date:6/29/2015)... (PRWEB) , ... June 30, 2015 , ... ... a set of revised Guidelines for Neuro Musculoskeletal Thermography and Sympathetic Skin Response ... original Guidelines that were first published in 2006, are intended to aid physicians ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, ... surgeon, Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of ... including Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... within the weekend edition of USA TODAY. This 12-page, glossy, full-color special section ... Today in highly targeted markets totaling approximately 450,000 copies, with an estimated readership ...
Breaking Medicine News(10 mins):Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 2Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 3Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 2Health News:Aespala Medspa and Plastic Surgery Welcomes New Plastic Surgeon to Oak Brook, IL Office 3Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 2Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2
... Jan. 18 Hyland,s, Inc. wants to,remind parents ... flu,season, Hyland,s homeopathic medicines remain a safe and ... cough and cold,symptoms., Today, the Food and ... over-the-counter (OTC) cough and cold,products in children under ...
... 18 175 students from,the Academy of Columbus, an ... sixth annual Give Kids A Smile! Day state kick-off ... kick-off will be held in the Atrium at the,Ohio ... Ohio State University College of Dentistry, legislators and other,dignitaries ...
... San Diego Supercomputer Center and other parts of the ... Parkinsons Disease, fusion energy and climate change - were ... (DOE) as part of its 2008 Innovative and Novel ... In total, the DOEs Office of Science awarded a ...
... in 2 men taking the product , , FRIDAY, Jan. ... as a dietary supplement appears to have contributed to ... researchers report. , "There were things on the label ... the product that were not on the label," said ...
... who do not have osteoporosis , , FRIDAY, Jan. 18 ... downplay the risks of prescribing bone-strengthening drugs for women ... osteoporosis, a new report claims. , Drugs such as ... fractures of women with osteoporosis, according to the article ...
... Builder and Job Postings Part of Available Resources-, ... ongoing effort to,ensure this group of returning wounded ... veterans, Wounded Warrior Project has expanded,their ever-evolving battery ... Warriors to Work (WtoW) initiative., The Warriors ...
Cached Medicine News:Health News:Hyland's Cough and Cold Medicines Remain a Safe and Effective Option for Toddlers and Young Children 2Health News:Statehouse Atrium to be Site for Children's Dental Access Event - Ohio Legislators to Mingle With Children and Dentists for This Free Care Event! 2Health News:DOE awards supercomputing time to UCSD, SDSC researchers 2Health News:DOE awards supercomputing time to UCSD, SDSC researchers 3Health News:Mislabled Supplement Spurred Prostate Cancer: Report 2Health News:Mislabled Supplement Spurred Prostate Cancer: Report 3Health News:Bone-Strengthening Drugs May Be Overprescribed 2Health News:Bone-Strengthening Drugs May Be Overprescribed 3Health News:Wounded Warrior Project (WWP) Expands Service Offerings for Injured Soldiers with the New 'Warriors to Work' Program 2
... Utilizing breakthrough electro-optical and rotary ... SUPRA is capable of obtaining ... pupils as narrow as 2.0mm. ... precise diagnostic results when dealing ...
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Highly concentrated daily cleaner with Microclens beads for superior cleaning action....
Medicine Products: